Kala Pharmaceuticals Inc.
KALA
NGS
Sector: Healthcare
Industry: Biotechnology
0.22
USD
0.00
(1.45%)
Optionable: Yes Market Cap: 13 M 90-day average vol: 1,098,338
Previous close: 0.2214 Open: 0.2244 Bid: 0.236 Ask: 0.236
52 week range
0.21 2.72
Last updated: Tuesday 4th October 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 1.56 |
Price per Book TTM ($) | 2.94 |
PE Ratio (TTM) | -0.10 |
Book Value per Share ($) | 0.94 |
5 Year PE Range | -56.3 , -1.4 |
Returns
7 Day Return | -1.71% | |
1 Month Return | -31.73% | |
3 Month Return | -27.55% | |
1 Year Return | -91.29% | |
3 Year Return | -94.43% | |
5 Year Return | -99.02% | |
YTD Return | -81.44% |
Risk
Custom Beta One Year | 1.04 |
Custom Beta Three Years | 0.55 |
Beneish M Score | -3.56 |
Altman Z Score | -7.71 |
Financial Health
Technicals
RSI (14 Day) | 28.88 |
14 Day SMA ($) | 0.27 |
14 Day EMA ($) | 0.26 |
Money Flow Index | 39.21 |
Average True Range | 0.02 |
50 Day SMA ($) | 0.31 |
200 Day SMA ($) | 0.69 |
ADX | 49.29 |
MACD | -0.03 |
Growth
Free Cash Flow QoQ Growth | 5.88% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -15.56% |
Revenue QoQ Growth | 53.06% |
EPS YoY Growth | 0.00% |
Profitability
Return on Assets TTM (%) | -91.03 |
Profit Margin TTM (%) | -1529.0 |
Return on Equity TTM (%) | -518.81 |
Return on Capital TTM (%) | -107.2 |
Interest Coverage Ratio | -15.30 |
Gross Margin TTM (%) | 41.9 |
News
Financials
KALA Income Statement
Annual
| Invalid date | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 45000 | 0 | 0 | 0 | 6 M | 6 M | 11 M | |
| Cost of sales | -330000 | -297000 | -643000 | -352000 | 1 M | 2 M | 3 M | |
| Gross operating profit | 45000 | 0 | 0 | 0 | 4 M | 3 M | 7 M | |
| Selling Gen & administrative expense | 5 M | 8 M | 11 M | 35 M | 65 M | 81 M | 105 M | |
| Research & development expense | 11 M | 25 M | 29 M | 29 M | 27 M | 18 M | 12 M | |
| Operating income | -16 M | -33 M | -40 M | -65 M | -88 M | -96 M | -109 M | |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other income net | -132000 | 122000 | -2 M | -390000 | 0 | 0 | -25 M | |
| Pre-tax Income (EBT) | -17 M | -33 M | -42 M | -67 M | -94 M | -104 M | -143 M | |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net income from total operations | -17 M | -33 M | -42 M | -67 M | -94 M | -104 M | -143 M | |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total net income | -17 M | -33 M | -42 M | -67 M | -94 M | -104 M | -143 M | |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| Net income available for common | -17 M | -33 M | -42 M | -67 M | -94 M | -104 M | -143 M | |
| Depreciation | 330000 | 297000 | 643000 | 352000 | 843000 | 907000 | 997000 | |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating income before depreciation (EBITDA) | -16 M | -32 M | -41 M | -63 M | -85 M | -95 M | -133 M | |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Basic EPS total | -0.97 | -2.2 | -3.71 | -2.49 | -2.76 | -1.99 | -2.19 | |
| Diluted EPS total | -0.97 | -2.2 | -3.71 | -2.49 | -2.76 | -1.99 | -2.19 |
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONSGet started today